# TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors

> **NCT06487663** · NA · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable
- Cholangiocarcinoma Non-resectable
- Liver Metastases
- Liver Malignant Tumors

## Interventions

- **PROCEDURE:** TACE with ICI

## Key facts

- **NCT ID:** NCT06487663
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-10-27
- **Primary completion:** 2025-10-27
- **Final completion:** 2026-10-27
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06487663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06487663, "TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06487663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*